Literature DB >> 9330465

Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination.

M Böttiger1, M Forsgren.   

Abstract

Two different strategies for the prevention of rubella-induced malformations have now been practised in Sweden, both reaching 90% or more of the target populations. The first was initiated in 1973-1974 and targeted schoolgirls, susceptible women after pregnancy and women at special risk. The second programme-a two-dose measles, mumps, rubella vaccination (MMR) of both boys and girls at the ages of 18 months and 12 years-was introduced in 1982. The percentage of susceptible pregnant women was gradually reduced from 12% in 1975 to 2.8% in 1987 and to just below 2% in 1994. The majority of the non immune are unvaccinated, these being either Swedes born before 1963 or immigrants. Before 1974 on average 14 severely rubella damaged children were reported yearly. Between 1975 and 1985 only a mean of two cases per year were recorded. Since 1985 no child with the rubella syndrome has been registered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330465     DOI: 10.1016/s0264-410x(97)00068-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

2.  Neighbourhood Deprivation, Individual-Level and Familial-Level Socio-demographic Factors and Risk of Congenital Heart Disease: A Nationwide Study from Sweden.

Authors:  Xinjun Li; Jan Sundquist; Tsuyoshi Hamano; Bengt Zöller; Kristina Sundquist
Journal:  Int J Behav Med       Date:  2016-02

Review 3.  Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

Authors:  Justin M Hintze; James P O'Neill
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-11       Impact factor: 2.503

4.  Phylogenetic analysis of rubella viruses involved in congenital rubella infections in France between 1995 and 2009.

Authors:  Christelle Vauloup-Fellous; Judith M Hübschen; Emily S Abernathy; Joseph Icenogle; Nicolas Gaidot; Pascal Dubreuil; Isabelle Parent-du-Châtelet; Liliane Grangeot-Keros; Claude P Muller
Journal:  J Clin Microbiol       Date:  2010-05-12       Impact factor: 5.948

5.  Comparison of four methods using throat swabs to confirm rubella virus infection.

Authors:  Zhen Zhu; Wenbo Xu; Emily S Abernathy; Min-Hsin Chen; Qi Zheng; Tongzhan Wang; Zhenying Zhang; Congyong Li; Changyin Wang; Weikuan He; Shujie Zhou; Joseph Icenogle
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

Review 6.  Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians.

Authors:  José Ramet; Diego van Esso; Zsofia Meszner
Journal:  Eur J Pediatr       Date:  2010-08-05       Impact factor: 3.860

7.  Prenatal characteristics of infants with a neuronal migration disorder: a national-based study.

Authors:  Estelle Naumburg; Bo Strömberg; Helle Kieler
Journal:  Int J Pediatr       Date:  2012-04-03

8.  Modelling the effect of a booster vaccination on disease epidemiology.

Authors:  M E Alexander; S M Moghadas; P Rohani; A R Summers
Journal:  J Math Biol       Date:  2005-11-10       Impact factor: 2.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.